Key facts
- QLi5 Therapeutics’s last known valuation is $13.5M (Dec 2021).
- It has raised $21.9M; the latest was Later Stage VC ($6.2M) in Jan 2026.
- Notable investors include Atinum Investment, DAOL Investment, Khanu Management, Lead Discovery Center, Max Planck Institute — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for QLi5 Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for QLi5 Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About QLi5 Therapeutics
Operator of a payload platform technology intended to scale to various indications. The company specializes in treating cancers and inflammatory and autoimmune disorders, enabling medical professionals to expand the treatment area for diseases.
- Sector
- Healthcare
- HQ
- Dortmund, Germany
- Founded
- 2019
- Website
- qli5tx.com/
- Ownership
- Privately Held (backing)
QLi5 Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in QLi5 Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on QLi5 Therapeutics in its N-PORT filings yet. We sweep new filings monthly.